![]() ECOG performance status was determined to be an independent prognostic factor in patients with LC-CTD. The presence of CTD, sex, ECOG performance status, and tumor-node-metastasis clinical stage were the independent prognostic factors in all patients with non–small cell LC (NSCLC). 35 months HR, 26.009 p < 0.001) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment between patients with AC with and without CTDs. A significant difference was observed in mPFS and mOS (6 months vs. The median progression-free survival (mPFS) and overall survival (mOS) of first-line chemotherapy did not differ between patients with lung adenocarcinoma (AC) with and without CTDs. The Eastern Cooperative Oncology Group (ECOG) performance score for LC-CTD patients was worse than that for matched non-CTD LC patients. Results: The median duration from the diagnosis of CTDs to LC was 17 years. Medical records, therapeutic efficacy of cancer, and outcomes were analyzed. Methods: This retrospective cohort study investigated 29 patients with LC with CTDs, and 116 patients with LC without CTDs were enrolled as case-matched control cohorts. Evidence supports that poor survival may be associated with the presence of CTDs in patients with LC. 2Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, Chinaīackground: Studies have demonstrated a close association between connective tissue diseases (CTDs) and lung cancer (LC). ![]() ![]() 1Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Ningning Li 1†, Liwei Gao 2†, Chunmei Bai 1*, Lin Zhao 1 and Yajuan Shao 1 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |